BMS-754807

Catalog No.S1124

BMS-754807 Chemical Structure

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Size Price Stock Quantity  
USD 180 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

1 Customer Review

  • Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
Features Muti-inhibitor of the IGR-1R/IR family.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal M2HLO2tqdmG|ZTDhd5NigQ>? NUHSSpVWcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDJS2YuOVJiKFnDOVAhRSBzM37NLUBidmRidHjlJIRwf26|dILlZY0hfGG{Z3X0d{BCc3RiKFnDOVAhRSB{Mn7NLUBidmRiTVHQT{ApUUN3MDC9JFE{dk1r MmHzNVk4PzhyMkS=
IGF-Sal NHPDPY9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoHpTWM2OD15IH7N MoTqNVk4PzhyMkS=
CCRF-CEM (ALL) NHvKZWRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFm2UZh,PSEQvF2= MUfEUXNQ NXvDO3JKUUN3ME2xMlI{QSEQvF2= NGXxRnQyQTl7NkK3Ni=>
PC3 MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXf+OUDPxE1? NWPrfmtJTE2VTx?= MXjJR|UxRTBwOU[1JO69VQ>? MoX6NVk6QTZ{N{K=
JD MlzQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3W2O542KM7:TR?= NFnTSHRFVVOR MXnJR|UxRTBwM{mxJO69VQ>? MXixPVk6PjJ5Mh?=
DU145 NG[x[WZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVz+OUDPxE1? NXfZXGQ1TE2VTx?= M3\KcmlEPTB;MT60OlUh|ryP NEPqOWwyQTl7NkK3Ni=>
KAG Ml\wS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVn+OUDPxE1? M4ey[mROW09? MV;JR|UxRTFwNk[1JO69VQ>? NYS1V|M{OTl7OU[yO|I>
K-562 (CML) NGr1[YlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXf+OUDPxE1? MWfEUXNQ NVv3UIU5UUN3ME2yMlMxOiEQvF2= M1[1T|E6QTl4Mkey
B6-P210 (Murine ALL) NFP1dYNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWPlcIpLhjVizszN MnjiSG1UVw>? MVjJR|UxRTFwMkmzJO69VQ>? MlPaNVk6QTZ{N{K=
LN CAP-FGC MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXG1Uo1IhjVizszN Ml:wSG1UVw>? M4PnNWlEPTB;MT60N|Qh|ryP MWWxPVk6PjJ5Mh?=
VW NV;nN45rT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3LFTJ42KM7:TR?= NUPSUosxTE2VTx?= Mn63TWM2OD1yLkCxPUDPxE1? NVu2clVbOTl7OU[yO|I>
MV411 (B Myelomonocytic) NIDEfllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnfYglUh|ryP M4Dib2ROW09? NIjNVZdKSzVyPUCuN|Mh|ryP MlPjNVk6QTZ{N{K=
MDA-PCa-2b Mmr4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUfWUmFwhjVizszN M1zGfmROW09? NGf1WYxKSzVyPUCuNFk5KM7:TR?= NXPEPJc1OTl7OU[yO|I>
LG NVezd2g5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnnmglUh|ryP MV3EUXNQ M2nWXGlEPTB;MD6wN|gh|ryP MX6xPVk6PjJ5Mh?=
RS411 (B cell precursor-ALL) NFPwdoRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnW2glUh|ryP M2PjbWROW09? MWHJR|UxRTBwMUCyJO69VQ>? M4PhS|E6QTl4Mkey
22-r-1 MmjiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXzPWHNzhjVizszN NF3DUXBFVVOR MVjJR|UxRTBwMUe1JO69VQ>? NGDz[oQyQTl7NkK3Ni=>
5838 NWSxWIVrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFXHXHJ,PSEQvF2= M3nYNWROW09? NXvhWHNsUUN3ME2wMlA{PCEQvF2= Ml;oNVk6QTZ{N{K=
P388 (Murine) MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mnq3glUh|ryP M4DpbWROW09? Mny3TWM2OD12LkK3JO69VQ>? MkKyNVk6QTZ{N{K=
A2780/S MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmXxglUh|ryP NWDXNHVGTE2VTx?= NHziS2lKSzVyPUCuNVIzKM7:TR?= NW\Qc3dzOTl7OU[yO|I>
RDES NHq5ZZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnXuglUh|ryP MmDBSG1UVw>? MmDFTWM2OD1yLkCxNkDPxE1? NXS0RVJmOTl7OU[yO|I>
B6-T315I (Murine B-ALL) MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXjUcpVXhjVizszN NH3vXZVFVVOR NX:3O3R4UUN3ME2yMlg{KM7:TR?= NGLIdY4yQTl7NkK3Ni=>
TOV 112D NVXIfZdUT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlLQglUh|ryP Mkn6SG1UVw>? Mn3XTWM2OD1{LkG0OkDPxE1? M3uzTlE6QTl4Mkey
TC32 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYOxWoNuhjVizszN NHPBUG1FVVOR MlrKTWM2OD1yLkCwPEDPxE1? NH64SJQyQTl7NkK3Ni=>
HL60 (acute myelocytic) M3[4fGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVf+OUDPxE1? MV\EUXNQ MUXJR|UxRTBwMUKg{txO Ml64NVk6QTZ{N{K=
TOV 21G M3rGW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlWwglUh|ryP MlfkSG1UVw>? M3PUOWlEPTB;ND6yO|kh|ryP NXrJXHBuOTl7OU[yO|I>
TC71 NYjWW|lPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWP+OUDPxE1? NV3lR2JETE2VTx?= M2\PO2lEPTB;MD6wNVQh|ryP NXqzTWVbOTl7OU[yO|I>
HPN-ALL (T-cell) M13OS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkTDglUh|ryP MmDpSG1UVw>? NVf2ToEyUUN3ME2wMlUzKM7:TR?= M4qzcFE6QTl4Mkey
A2780R MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIna[WF,PSEQvF2= MV7EUXNQ Mmj6TWM2OD1zLkW2OEDPxE1? MlThNVk6QTZ{N{K=
Rh1 NWPBfFBTT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{\JdZ42KM7:TR?= MXvEUXNQ M4jpPWlEPTB;MD6wNlch|ryP NVPXT2Q5OTl7OU[yO|I>
Kasumi-1 (acute myeloid) M1zzVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXf+OUDPxE1? M1PYU2ROW09? MlTSTWM2OD1yLkG2JO69VQ>? M4WwVlE6QTl4Mkey
sk-ov-3 M{L4dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYrEVXdbhjVizszN NHrWNVlFVVOR NH3hSY1KSzVyPUWuNUDPxE1? M1fZR|E6QTl4Mkey
ME M3nMNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MonIglUh|ryP NInpdJNFVVOR Mo\xTWM2OD1yLkCxOUDPxE1? MknaNVk6QTZ{N{K=
L1210 (Murine lymphocytic) NHPt[5lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3HtOp42KM7:TR?= MWXEUXNQ MlzDTWM2OD1{LkO5JO69VQ>? NH7VeW4yQTl7NkK3Ni=>
sw-626 M2D3Rmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mnm3glUh|ryP MY\EUXNQ Mlm1TWM2OD1{LkOwOkDPxE1? M1LBTFE6QTl4Mkey
CTR M4HrSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVHMT3pYhjVizszN M4PSWGROW09? NFTOeVRKSzVyPUCuNlU{KM7:TR?= NYXDN3VMOTl7OU[yO|I>
ML2 (Myelomonocytic) NHnoeYNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHXycJR,PSEQvF2= M171R2ROW09? MUXJR|UxRTBwMEmg{txO NFOyWnMyQTl7NkK3Ni=>
ovcar-3 M4nnS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUjiSVJMhjVizszN NGLVO5JFVVOR NUmz[JNJUUN3ME21JO69VQ>? MXuxPVk6PjJ5Mh?=
Rh36 MoPSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYWx[pZqhjVizszN MmjDSG1UVw>? MkO4TWM2OD1zLkSzNkDPxE1? M2LZdVE6QTl4Mkey
MOLM-13 (acute myeloid) NHTVPJVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVXYSFdWhjVizszN M3;PdmROW09? MnT3TWM2OD1yLkSyJO69VQ>? MX6xPVk6PjJ5Mh?=
ovcar-4 MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3yxXZ42KM7:TR?= NGjjXVNFVVOR M33aUmlEPTB;MTFOwG0> NG\mbG8yQTl7NkK3Ni=>
Rh41 MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MV3+OUDPxE1? NUfIS4Q2TE2VTx?= NGPTU5BKSzVyPUCuNFA2KM7:TR?= MVqxPVk6PjJ5Mh?=
Mutz 2 (acute myeloid) MkG1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1j6[542KM7:TR?= MUnEUXNQ MVvJR|UxRTFwMUWg{txO NV7jRW1xOTl7OU[yO|I>
ovcar-5 M1fCWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH33S4R,PSEQvF2= NULSTINHTE2VTx?= MXnJR|UxRTBwMEWg{txO MVexPVk6PjJ5Mh?=
RD1 M4S5N2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWH+OUDPxE1? Mmf0SG1UVw>? NWTQe2dOUUN3ME2wMlA3QCEQvF2= M2j2bVE6QTl4Mkey
OCI-AML 2 (acute myeloid) MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUfUdG9{hjVizszN M3XMUGROW09? MXLJR|UxRTNwM{Og{txO MlnONVk6QTZ{N{K=
786-O M1vxcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{jpUZ42KM7:TR?= MXfEUXNQ NVzrZ|F4UUN3ME2xMlY1PyEQvF2= M4Dyc|E6QTl4Mkey
A673 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXn+OUDPxE1? MYTEUXNQ NXTFXJEyUUN3ME2wMlQxQCEQvF2= NEnyTIMyQTl7NkK3Ni=>
TALL-1 (T-cell) NWqz[W1oT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NF\RWlR,PSEQvF2= MnezSG1UVw>? M3vqW2lEPTB;MT6yPEDPxE1? NIXVOWsyQTl7NkK3Ni=>
151-B NIP4OWFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXLTR44xhjVizszN MXHEUXNQ NHHid2dKSzVyPUKuOlch|ryP NIjsTHEyQTl7NkK3Ni=>
PFSK-1 NU\TVYRwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUD+OUDPxE1? NVXRcVhxTE2VTx?= MXHJR|UxRTBwMUOyJO69VQ>? M3;Z[lE6QTl4Mkey
THP-1 M2Dod2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHmyWFF,PSEQvF2= NH[5U4dFVVOR M2TtN2lEPTB;Nj61PEDPxE1? MmPUNVk6QTZ{N{K=
HEK293 NHr2dm1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYX+OUDPxE1? NIe1TZVFVVOR MnXtTWM2OD1yLkmxOUDPxE1? MV2xPVk6PjJ5Mh?=
DAOY NU\xO25vT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUPNcHRIhjVizszN MknuSG1UVw>? NH;xN4ZKSzVyPUGuPVc6KM7:TR?= NYC1SnlHOTl7OU[yO|I>
SET2 NXXKRXl3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnjjglUh|ryP NUfMTWpvTE2VTx?= MXjJR|UxRTBwMkm4JO69VQ>? NH;DWIUyQTl7NkK3Ni=>
HTB-46 NUX3dFZIT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWr+OUDPxE1? MULEUXNQ NYrUVplOUUN3ME21MlI2KM7:TR?= Mk\0NVk6QTZ{N{K=
SK-NAS NW\CXIFmT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVr+OUDPxE1? MX;EUXNQ MUDJR|UxRTBwNEm3JO69VQ>? M3XaVVE6QTl4Mkey
CTLL2 M3rTZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXT+OUDPxE1? NYnNVIlOTE2VTx?= NED0[pVKSzVyPkGuNFAh|ryP Mn7iNVk6QTZ{N{K=
HTB-47 NES0d|hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MV3+OUDPxE1? M4HsV2ROW09? MWTJR|UxRTJwMEW2JO69VQ>? M1nPdVE6QTl4Mkey
LAN-1 NEPHdWtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2DZdp42KM7:TR?= NH7VdXNFVVOR M2DufWlEPTB;MD6wOEDPxE1? M1PlT|E6QTl4Mkey
ST486 NFXXbIdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml;MglUh|ryP MlrHSG1UVw>? NIiybWVKSzVyPUGuNVkh|ryP MmPqNVk6QTZ{N{K=
HS766T NIPrSWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEf6cJN,PSEQvF2= NGfFfI1FVVOR NYHPXml5UUN3ME2yMlAxOSEQvF2= M2Wy[lE6QTl4Mkey
IMR-32 NGHONllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NF33dVl,PSEQvF2= NULPWIdLTE2VTx?= M3yzUmlEPTB;MD6yOlEh|ryP NUiydGhKOTl7OU[yO|I>
Daudi (Burkitt's) MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVfld21XhjVizszN NV3pTY5mTE2VTx?= MYTJR|UxRTJwNkO3JO69VQ>? MXyxPVk6PjJ5Mh?=
Aspc-1 NUTkVGd4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NX7idYt1hjVizszN MlfXSG1UVw>? NXXmbHdzUUN3ME2wMlM4QSEQvF2= M4DPcVE6QTl4Mkey
SK-NSH MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV;Rcpo6hjVizszN NUm3b2dOTE2VTx?= NX[xWGV6UUN3ME2wMlE{QSEQvF2= MoDkNVk6QTZ{N{K=
MEC-1 (Chronic B cell) Mn;1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3;2PZ42KM7:TR?= MUHEUXNQ M{nn[2lEPTB;Mj62N|ch|ryP NF:wPXkyQTl7NkK3Ni=>
Capan-2 NVvYdoE2T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NF\mdnF,PSEQvF2= M4nHbWROW09? M4rjTWlEPTB;MT63O|Qh|ryP NEDzdGMyQTl7NkK3Ni=>
SHSY5Y Ml7LS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX;+OUDPxE1? NITWTmZFVVOR NIDJNpdKSzVyPUCuNVA3KM7:TR?= MUSxPVk6PjJ5Mh?=
U937 (Histioocytic) MkC5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3nzbp42KM7:TR?= M{nBR2ROW09? NWHmNYY4UUN3ME61MlAxKM7:TR?= M33kblE6QTl4Mkey
Bxpc-1 M2jUbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUP+OUDPxE1? NH;5dIhFVVOR MVTJR|UxRTFwOUK0JO69VQ>? MkTONVk6QTZ{N{K=
Bxpc-3 NXq3S4oxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkDuglUh|ryP MUPEUXNQ M{PQ[2lEPTB-NT6wNEDPxE1? MoTDNVk6QTZ{N{K=
HTB-92 Mme5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4jtdp42KM7:TR?= MlrISG1UVw>? MkHpTWM2OD1zLkCyJO69VQ>? MWGxPVk6PjJ5Mh?=
OCI-LY10 (B-cell) NFXFWXFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2DZWZ42KM7:TR?= M3:x[2ROW09? MlPSTWM2OD1yLkS1JO69VQ>? NHnJSXkyQTl7NkK3Ni=>
PANC-1 M2O5PGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mo\5glUh|ryP NIPCWW5FVVOR MVHJR|UxRjVwMECg{txO M{HWeFE6QTl4Mkey
To184.T Mmj3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIP0Vnp,PSEQvF2= MXvEUXNQ M{i4TGlEPTB;MD60Olkh|ryP MY[xPVk6PjJ5Mh?=
OCI-LY19 (B-cell) MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGrtSHR,PSEQvF2= MXXEUXNQ MXjJR|UxRTBwNDFOwG0> M2nIcFE6QTl4Mkey
PANC-1 BM NHS4RoVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mm\tglUh|ryP M3vtVWROW09? NIjsO2VKSzVyPkWuNFAh|ryP NHy2WGEyQTl7NkK3Ni=>
SA-4 NHnJOmRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIPW[lN,PSEQvF2= NYnEfldCTE2VTx?= NFO1S5BKSzVyPUGuN|AyKM7:TR?= M1O2S|E6QTl4Mkey
RPMI 8226 MmGyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NEjofo1,PSEQvF2= NFjuc2ZFVVOR MXvJR|UxRTFwMkmzJO69VQ>? M1\3W|E6QTl4Mkey
HPAF-II M4D3Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MX;+OUDPxE1? M4PoSGROW09? MlrCTWM2OD1yLk[0OEDPxE1? M1njeVE6QTl4Mkey
SHP-77 NFfpNVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUn+OUDPxE1? MYnEUXNQ MXXJR|UxRTFwOEi4JO69VQ>? MYmxPVk6PjJ5Mh?=
U266 B1 MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWmwO483hjVizszN MUXEUXNQ NHrobVlKSzVyPUGuOlY6KM7:TR?= M2TUSlE6QTl4Mkey
Hs700t NWnOXXR{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYP+OUDPxE1? NWnNOlNbTE2VTx?= MXnJR|UxRTBwMkOxJO69VQ>? NYHtZmRGOTl7OU[yO|I>
NCI-446 M{i1bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHLBN2l,PSEQvF2= NX7OdlVKTE2VTx?= NX;ScI5YUUN3ME2xMlE2PCEQvF2= MoHMNVk6QTZ{N{K=
H929 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEPU[G9,PSEQvF2= NXjUOpZXTE2VTx?= M4nkZmlEPTB;MD6wNVQh|ryP NYHqOYtWOTl7OU[yO|I>
PL45 M4TtVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXT+OUDPxE1? NHPuPIZFVVOR NXjrPXhnUUN3ME2yMlI2PSEQvF2= M3\5SFE6QTl4Mkey
NCI-H383 MoTLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYH+OUDPxE1? NF7yb4ZFVVOR MVfJR|UxRjVwMECg{txO MkiwNVk6QTZ{N{K=
JJN3 MmPRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWH+OUDPxE1? NX6zS3g{TE2VTx?= MnPlTWM2OD1{LkSzN{DPxE1? M{DPeVE6QTl4Mkey
SU.86.86 NF\2NmlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3[2bZ42KM7:TR?= MnjYSG1UVw>? NHnscXlKSzVyPUKuOlczKM7:TR?= MlzhNVk6QTZ{N{K=
H1299 NUXne4c1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEH4Xnl,PSEQvF2= MkDrSG1UVw>? MXvJR|UxRjVwMECg{txO MVWxPVk6PjJ5Mh?=
MDA-MB-468 MoHSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4HvUZ42KM7:TR?= NWDmSFU{TE2VTx?= MXfJR|UxRTBwNUC0JO69VQ>? NXHGNW16OTl7OU[yO|I>
SW1990 NX2zTYJ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYTmXnVzhjVizszN Moe2SG1UVw>? NWrRRWdHUUN3ME2wMlgzPiEQvF2= M3zCSlE6QTl4Mkey
Calu-6 NGTPcIFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXXBXGpUhjVizszN NHG4fG9FVVOR NXLTc4R[UUN3ME61MlAxKM7:TR?= NIO3OpIyQTl7NkK3Ni=>
MDA-MB-231 MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWHFc3FWhjVizszN M3nOdGROW09? M17T[WlEPTB;MT62OFgh|ryP MYmxPVk6PjJ5Mh?=
SW-684 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFHKfJd,PSEQvF2= M2L1[GROW09? Ml7TTWM2OD53LkCwJO69VQ>? NF72dZUyQTl7NkK3Ni=>
H209 NXvIbYRsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXHGcpdHhjVizszN NHzmXZBFVVOR NFLhWplKSzVyPUGuNVk{KM7:TR?= NHv6[3gyQTl7NkK3Ni=>
MDA-MB-231T M{D6Nmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVmyepEyhjVizszN Mnf1SG1UVw>? NUG0VnJ3UUN3ME61MlAxKM7:TR?= MWCxPVk6PjJ5Mh?=
HT1080/S Mn25S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NW\2cHF7hjVizszN MUXEUXNQ M1f4SGlEPTB;MD61N|Eh|ryP MkDoNVk6QTZ{N{K=
H526 0.044 NEThWHRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3[5bp42KM7:TR?= Mn3DSG1UVw>? MnLPTWM2OD1yLkC0OEDPxE1? NI\ISFkyQTl7NkK3Ni=>
DU4475 2.431 MoHKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mki2glUh|ryP MWXEUXNQ NY\nXlhEUUN3ME2yMlQ{OSEQvF2= NImxb2YyQTl7NkK3Ni=>
HCT116 NXjhPW1nT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVP+OUDPxE1? NXzab|JCTE2VTx?= M3XuPWlEPTB;MD64OVIh|ryP NXP2b2lTOTl7OU[yO|I>
M109 MnT4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MljlglUh|ryP MoOySG1UVw>? MXTJR|UxRTFwMEW1JO69VQ>? M3vabFE6QTl4Mkey
BT549 Mn3PS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmjlglUh|ryP NFrBR2hFVVOR Ml7DTWM2OD1zLk[0OUDPxE1? NEK1PZEyQTl7NkK3Ni=>
HCT116/VM46 NFXnSJNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmLxglUh|ryP MUnEUXNQ NHX0emVKSzVyPUGuO|AzKM7:TR?= MYGxPVk6PjJ5Mh?=
H460 NX3aOYhPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVj+OUDPxE1? NHe0dYNFVVOR NXy3cY1[UUN3ME2wMlc6PSEQvF2= NF25cJMyQTl7NkK3Ni=>
MCF-7 NWWw[HVQT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVm4RoRDhjVizszN MVPEUXNQ M2XadWlEPTB;MD6wNVYh|ryP MX[xPVk6PjJ5Mh?=
GEO NEfIOY1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4HwfJ42KM7:TR?= M13mR2ROW09? NFjXZoRKSzVyPUCuN|U3KM7:TR?= M2jPeFE6QTl4Mkey
H441 0.646 MmP4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnXkglUh|ryP NV2xdpJ6TE2VTx?= NUjTS45TUUN3ME2wMlY1PiEQvF2= NFvDcFIyQTl7NkK3Ni=>
MCF-7-807R Mn;GS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH74Znp,PSEQvF2= MlPSSG1UVw>? MYTJR|UxRTBwNEmg{txO MXWxPVk6PjJ5Mh?=
Colo205 NEPkcVJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmnaglUh|ryP NVLuT2UzTE2VTx?= MmPLTWM2OD1yLkGwOEDPxE1? MUixPVk6PjJ5Mh?=
H292 NFnuPZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmDQglUh|ryP NHvidI9FVVOR M3HxXGlEPTB;MD63PFgh|ryP NUnSdphMOTl7OU[yO|I>
BT474 (S) NEGyPW1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkjLglUh|ryP MYHEUXNQ NH;3XlhKSzVyPUKuOFA{KM7:TR?= Ml7FNVk6QTZ{N{K=
HT-29 NYCzVnMyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkXrglUh|ryP MnG1SG1UVw>? NHzzRXdKSzVyPUKuNVA{KM7:TR?= MYOxPVk6PjJ5Mh?=
A549 NFjUfFVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M13IfZ42KM7:TR?= NWP3dJhMTE2VTx?= M2TERWlEPTB;MD62O|Uh|ryP M3rvV|E6QTl4Mkey
BT474-M1 MknQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIm5b2J,PSEQvF2= NXe2N5ZqTE2VTx?= MoixTWM2OD1{LkO2OUDPxE1? MY[xPVk6PjJ5Mh?=
SW480 MlvpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWLMbW42hjVizszN NHLvb2FFVVOR NVnnVos2UUN3ME61MlAxKM7:TR?= NUOzOpA3OTl7OU[yO|I>
L2987 M1;tWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1mwUp42KM7:TR?= MXjEUXNQ NVjES4hxUUN3ME2wMlQ1OiEQvF2= MmrUNVk6QTZ{N{K=
AU565 NVW3VmdbT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmDxglUh|ryP MUPEUXNQ NWXaUoFuUUN3ME20Mlk4KM7:TR?= MkDQNVk6QTZ{N{K=
SW403 M2jhd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXf+OUDPxE1? NHrHeY5FVVOR MVPJR|UxRTBwMkKg{txO NHvTcnkyQTl7NkK3Ni=>
H1437 MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4P4b542KM7:TR?= NHnPZ2tFVVOR MXTJR|UxRTBwNUKzJO69VQ>? NYXOOZMyOTl7OU[yO|I>
BT-20 NXS4fGI3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVi4Zog3hjVizszN MUXEUXNQ M2HXVGlEPTB;Mz61OlIh|ryP MmDsNVk6QTZ{N{K=
Colo320HSR MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYDPXHZ1hjVizszN MV;EUXNQ Ml;UTWM2OD1yLkCxNUDPxE1? MkfsNVk6QTZ{N{K=
H2087 NFfXdWJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3OxU542KM7:TR?= M2TXOmROW09? NH;5UZZKSzVyPkGuNFAh|ryP NYX5PJQ3OTl7OU[yO|I>
HCC1419 MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWrTflJHhjVizszN NET5bHpFVVOR Mn\STWM2OD1{LkWxO{DPxE1? Mk\iNVk6QTZ{N{K=
WiDr NYnHfo5FT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUnVW2hOhjVizszN M1jyXGROW09? MnfYTWM2OD1yLkC3OkDPxE1? MoGyNVk6QTZ{N{K=
H661 0.573 NYezcVRTT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVL+OUDPxE1? Ml;ZSG1UVw>? NHTwNFBKSzVyPUCuOVc{KM7:TR?= M{HBbVE6QTl4Mkey
HCC-38 NV[4UmpDT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3y0dp42KM7:TR?= NHe1V3RFVVOR Mk[2TWM2OD53LkCwJO69VQ>? NYLFdG5VOTl7OU[yO|I>
LS174T NHniPXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXv+OUDPxE1? NUDBNWVXTE2VTx?= M{freGlEPTB;MD61N|Uh|ryP NYC1dWs1OTl7OU[yO|I>
H211 MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEe1VHZ,PSEQvF2= M3;ofWROW09? M3LQdmlEPTB;MD63N|Mh|ryP M{DMeFE6QTl4Mkey
HCC70 NYfCNJFTT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWT2PWNmhjVizszN MVfEUXNQ NIHIfVRKSzVyPUGuOVUh|ryP NIi1TIwyQTl7NkK3Ni=>
SW116 Mof2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYfsXHpyhjVizszN MVjEUXNQ Mn7kTWM2OD1yLkC2O{DPxE1? M4\2NlE6QTl4Mkey
H513 M4jjOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MY\+OUDPxE1? NEDMbHdFVVOR MUfJR|UxRTRwNES4JO69VQ>? NIfadmUyQTl7NkK3Ni=>
MDA-MB-157 NYjqVYpVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX;+OUDPxE1? NGTTRXpFVVOR NILCdFNKSzVyPUCuNFM3KM7:TR?= MYWxPVk6PjJ5Mh?=
H2052 NV;HUFlWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX;+OUDPxE1? MU\EUXNQ M2i4bmlEPTB;MT6wOUDPxE1? NV7hbYlNOTl7OU[yO|I>
MDA-MB-415 NVvaU5NPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWDucVFChjVizszN NVvpSGVZTE2VTx?= NEjI[HVKSzVyPkWuNFAh|ryP MmPmNVk6QTZ{N{K=
DLD-1 NFrZN3JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1[1e542KM7:TR?= M4PufWROW09? M3vWNmlEPTB;MD65NFkh|ryP NYrtRWtxOTl7OU[yO|I>
H2595 Mnz3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NEXVeoJ,PSEQvF2= NInxOJFFVVOR MnLJTWM2OD12LkS3OUDPxE1? NEjkcIkyQTl7NkK3Ni=>
MDA-MB-435S MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV:2bYRLhjVizszN NE\zb2hFVVOR NVq4d4pRUUN3ME2xMlg3QSEQvF2= NFvpNZQyQTl7NkK3Ni=>
HCT15 NXHISFVVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmH4glUh|ryP MVfEUXNQ MY\JR|UxRjFwMECg{txO MmP4NVk6QTZ{N{K=
SK-Hep1 NVm2TmlvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoOzglUh|ryP NW\lOXhWTE2VTx?= M2XqOGlEPTB;MD6xOFYh|ryP MXqxPVk6PjJ5Mh?=
MDA-MB-436 M1foNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVThPXBrhjVizszN MnziSG1UVw>? NVjYbZZ{UUN3ME21MlUxOiEQvF2= Mkn0NVk6QTZ{N{K=
KM12C MmP6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUPCWYdlhjVizszN NF[1SoVFVVOR Ml7QTWM2OD1yLkC1OEDPxE1? NVuxWoc2OTl7OU[yO|I>
HEPG2 NXS3fmFFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NF:yUVR,PSEQvF2= MVLEUXNQ M4LhNmlEPTB;MD6wNlUh|ryP Mn20NVk6QTZ{N{K=
MDA-MB-453 NVjB[YtzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3\lfp42KM7:TR?= MYrEUXNQ NFLBcJJKSzVyPUGuPFY6KM7:TR?= M2niWlE6QTl4Mkey
KM12SM NYD2T3k1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4C4Wp42KM7:TR?= M4XsV2ROW09? M4nPTGlEPTB;MD6wOVkh|ryP MVmxPVk6PjJ5Mh?=
1483 MnjzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXv+OUDPxE1? MVvEUXNQ MV;JR|UxRTJwMUmg{txO NF;aeXoyQTl7NkK3Ni=>
Hs578t MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3zkOp42KM7:TR?= NVLQU3VLTE2VTx?= MkfBTWM2OD1zLkK4O{DPxE1? M3fhd|E6QTl4Mkey
LS180 Mn;kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFX2NFl,PSEQvF2= M4DTdWROW09? M322bmlEPTB;MD62PVYh|ryP MV[xPVk6PjJ5Mh?=
FaDu NVvz[oRTT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3\G[J42KM7:TR?= NF[3VYRFVVOR MYnJR|UxRTFwMkeg{txO M3LJZVE6QTl4Mkey
ZR-75-1 MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYn+OUDPxE1? MoLCSG1UVw>? M{jSbGlEPTB;Mj6wPFQh|ryP M2jVOlE6QTl4Mkey
LS513 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUL1T|ZbhjVizszN MlXFSG1UVw>? MonPTWM2OD1yLkGzOUDPxE1? M133bFE6QTl4Mkey
Detroit.562 NXnIcHdUT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUjlZ3JLhjVizszN M4D2U2ROW09? M33UPGlEPTB;MT6xOEDPxE1? NVK1bGJ3OTl7OU[yO|I>
ZR-75-30 M4nxO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlzaglUh|ryP NV7ZfYl7TE2VTx?= MUXJR|UxRjVwMECg{txO NYDKNIZWOTl7OU[yO|I>
RKO-PM MnjoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWjkZXFYhjVizszN NF;OTpZFVVOR NX;kXFNRUUN3ME2wMlI{OiEQvF2= NFLBbokyQTl7NkK3Ni=>
Cal.27 M{fDRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mk\uglUh|ryP MUTEUXNQ Mk\CTWM2OD1{IN88US=> MVWxPVk6PjJ5Mh?=
KPL4 NIPDbY5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NX60ZVRIhjVizszN NIrVO4pFVVOR MWnJR|UxRTFwMkWyJO69VQ>? MXuxPVk6PjJ5Mh?=
PKO-RM13 NGDuNm1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mk\SglUh|ryP M2\qSWROW09? NUjDOmczUUN3ME2wMlQzPSEQvF2= MmPuNVk6QTZ{N{K=
HS.53.T MnnqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVjGWlB[hjVizszN NYLCSo1[TE2VTx?= M13WdGlEPTB;MD63PUDPxE1? MmHNNVk6QTZ{N{K=
EMT6 M{CzUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUHiTXRihjVizszN M4HENWROW09? MYjJR|UxRTBwOEC2JO69VQ>? NXTj[3dCOTl7OU[yO|I>
SNU-C1 M2\1[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4fxeJ42KM7:TR?= MWjEUXNQ MVXJR|UxRTBwMEC3JO69VQ>? MlHONVk6QTZ{N{K=
SQCCY1 Mm\WS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWr+OUDPxE1? MYXEUXNQ NUPZbYZHUUN3ME2wMlc6KM7:TR?= MoPrNVk6QTZ{N{K=
SW480 M3zpb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYXaNZQ6hjVizszN MX;EUXNQ MmnHTWM2OD1yLkCzO{DPxE1? MVixPVk6PjJ5Mh?=
SCC9 NYHTdmZ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVn+OUDPxE1? NXqwZ45JTE2VTx?= NUD1bFZ6UUN3ME2wMlc2KM7:TR?= MYWxPVk6PjJ5Mh?=
SK-LMS-1 MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEHWU5d,PSEQvF2= M4\RXmROW09? NYG2[oZvUUN3ME2wMlY5PyEQvF2= NHH2THIyQTl7NkK3Ni=>
SCC25 NUfKXYJzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnfZglUh|ryP M3vlRWROW09? NFGwdlRKSzVyPUCuOlgh|ryP NWDu[mF6OTl7OU[yO|I>
U87 MnHxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGDkNVR,PSEQvF2= MlPmSG1UVw>? NUfwdIJFUUN3ME2wMlk2KM7:TR?= MUGxPVk6PjJ5Mh?=
SCC15 NVLQeXdFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWP+OUDPxE1? NFjaUndFVVOR Mo\DTWM2OD1yLk[3JO69VQ>? M4\G[lE6QTl4Mkey
T98G NHrjZVRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3\UUZ42KM7:TR?= MoLISG1UVw>? MmTOTWM2OD1zLkKxPEDPxE1? M1vseFE6QTl4Mkey
SCC4 MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkX4glUh|ryP MVfEUXNQ NIr0NGxKSzVyPUCuOlMh|ryP MXexPVk6PjJ5Mh?=
U118 NIC4RWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NI[zbHl,PSEQvF2= MoTnSG1UVw>? M{jQWmlEPTB;MT62NVgh|ryP MVexPVk6PjJ5Mh?=
TU167 M3nDc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWPx[HVShjVizszN M4Tac2ROW09? MX7JR|UxRTRwNUKg{txO MnLhNVk6QTZ{N{K=
NCI-H727 M1rDNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkXGglEx6oDMzszN MXHEUXNQ MW\JR|UxRTR{ODDuUS=> NHn2XWkzODN6NUe0Oy=>
NCI-H720 NHjJS4NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlG0glEx6oDMzszN NGn5U2xFVVOR MYPJR|UxRTJwODFOwG0> MknONlA{QDV5NEe=
NCI-H835 NF7vUmpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1zCfJ4yOOLCit88US=> NX;qNHY3TE2VTx?= MXXJR|UxRTFizszN MlPmNlA{QDV5NEe=
NCI-H727 NEHKVFFMcW6jc3WgZZN{[Xl? NWftOo1mhjFy4pEK{txO NEDXUHdFVVOR Mo\rbY5pcWKrdIOgZ49ve3SrdIX0bZZmKEmJRkHSJIF2fG:yaH;zdIhwenmuYYTpc44> M1\HRVIxOzh3N{S3
RD M3LDXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NED0WZJ,OTEkgJtOwG0> Ml7xTWM2OD1zLkGyJOK2VQ>? NWD1RlZxOjF{OUi3OFU>
Rh41 MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3zHcZ4yOOLCit88US=> NIf5PWRKSzVyPUCuNFchyrWP NWG4V2ZUOjF{OUi3OFU>
Rh18 MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXLqR4tVhjFy4pEK{txO M1i5O2lEPTB;ND65OkDDvU1? NFTafZMzOTJ7OEe0OS=>
Rh30 NH3IeYdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIXJcFN,OTEkgJtOwG0> M3jDW2lEPTB;MD6xPUDDvU1? NYjKcYRpOjF{OUi3OFU>
BT-12 MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWnCbmI2hjFy4pEK{txO MlHKTWM2OD1yLke4JOK2VQ>? NWXJSopbOjF{OUi3OFU>
CHLA-266 NFTtSXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4TROZ4yOOLCit88US=> NX7CZmw5UUN3ME2wMlg6KML3TR?= NIHFTnMzOTJ7OEe0OS=>
TC-71 NYrvc|A{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmfZglEx6oDMzszN M3OwO2lEPTB;MD6xNUDDvU1? NIXIXFQzOTJ7OEe0OS=>
CHLA-9 M1vlRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NU\QUpZDhjFy4pEK{txO NVizWFlOUUN3ME2wMlEzKML3TR?= M3nkZ|IyOjl6N{S1
CHLA-10 MmWxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mlf1glEx6oDMzszN MW\JR|UxRTBwNkKgxtVO M{DlZlIyOjl6N{S1
CHLA-258 MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXXpZm1UhjFy4pEK{txO M3nUNmlEPTB;MD6yO{DDvU1? Ml;rNlEzQTh5NEW=
GBM2 NULmOGs4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1ntbZ4yOOLCit88US=> MmC5TWM2OD1zLkS3JOK2VQ>? NWTSNZNQOjF{OUi3OFU>
NB-1643 MofXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIriVJR,OTEkgJtOwG0> NYDrOpcxUUN3ME2wMlEzKML3TR?= MnHVNlEzQTh5NEW=
NB-EBc1 NVuwWnFbT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXK3RZlDhjFy4pEK{txO NIXHeWxKSzVyPUCuN|UhyrWP NF;yNXozOTJ7OEe0OS=>
CHLA-90 NVS4PFVvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MV;+NVDjiIsQvF2= M3\iOmlEPTB;MD63O{DDvU1? MW[yNVI6QDd2NR?=
CHLA-136 NUSzRY82T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MW\+NVDjiIsQvF2= MVPJR|UxRTBwNUKgxtVO MYWyNVI6QDd2NR?=
NALM-6 MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYT+NVDjiIsQvF2= NXfM[5JMUUN3ME2wMlQ6KML3TR?= NWf1flVOOjF{OUi3OFU>
COG-LL-317 NFnnTItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MV3+NVDjiIsQvF2= NYP2V245UUN3ME2xMlM5KML3TR?= MkLYNlEzQTh5NEW=
RS4;11 MnnJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXX+NVDjiIsQvF2= MVLJR|UxRTBwM{igxtVO NFjoOXozOTJ7OEe0OS=>
MOLT-4 NYTrZ45{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFvle3B,OTEkgJtOwG0> M3e2eGlEPTB;MD61N{DDvU1? NXrvNFJoOjF{OUi3OFU>
CCRF-CEM M3ridWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnqwglEx6oDMzszN NGfHPYJKSzVyPUGuNVMhyrWP MWGyNVI6QDd2NR?=
Kasumi-1 NX;kXlZrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1zB[p4yOOLCit88US=> NGP4UnBKSzVyPUGuNkDDvU1? MUeyNVI6QDd2NR?=
Karpas-299 M1zZS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFvib4l,OTEkgJtOwG0> NYn3ZYNuUUN3ME2xMlY1KML3TR?= NX:zOItrOjF{OUi3OFU>
Ramos-RA1 M4HzTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUm4b2M6hjFy4pEK{txO MW\JR|UxRTFwM{GgxtVO NWCzRY9TOjF{OUi3OFU>
Rh30  NYLWenB5TnWwY4Tpc44h[XO|YYm= NF7IfW1qdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:|cHjvdplt[XSrb36= NFuwW2czPTl{NUO3PC=>
Rh41 MmW1SpVv[3Srb36gZZN{[Xl? NIHPUnRqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:|cHjvdplt[XSrb36= MUKyOVkzPTN5OB?=
RD NI\jTnNHfW6ldHnvckBie3OjeR?= M4T2[Ylv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= NG[4UIkzPTl{NUO3PC=>
A549 NGOwWW5McW6jc3WgZZN{[Xl? MXOwMlXjiIsQvF2= NUL3RYoyTE2VTx?= NVjBPGNpcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25? MnPVNlY6Ojh3N{i=
NCI-H358 M4\DVmtqdmG|ZTDhd5NigQ>? NWXjVWJKOC534pEK{txO MYjEUXNQ MoHRbY5pcWKrdIOgTWdHNUmUL1nSJIFkfGm4YYTpc44> NUnFUVlNOjZ7Mki1O|g>
A549 MXzGeY5kfGmxbjDhd5NigQ>? MWOwMlXjiIsQvF2= Mo\ZSG1UVw>? M1XMOYNifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt? NW[1b2VwOjZ7Mki1O|g>
NCI-H358 M2LtU2Z2dmO2aX;uJIF{e2G7 NGHtS4gxNjYkgJtOwG0> NWLGcYN[TE2VTx?= MY\jZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM Mnv1NlY6Ojh3N{i=
A549 Ml[3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWX+NVDjiIsQvF2= NGnNXpVFVVOR NF7FVVFKSzVyPUCuO|Yh|ryP MYOyOlkzQDV5OB?=
NCI-H358 NXTFbZdpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWD+NVDjiIsQvF2= NYPZVmtJTE2VTx?= MWHJR|UxRTFwMEmg{txO Mn23NlY6Ojh3N{i=
A549 MonzRZBweHSxc3nzJIF{e2G7 M{LPPVAvPeLCit88US=> M4jvdGROW09? NILMOpBqdmS3Y3XzJGFxd3C2b4Ppdy=> NYXpToh1OjZ7Mki1O|g>
NCI-H358 M1;kVGFxd3C2b4Ppd{Bie3OjeR?= NFLUSWYxNjYkgJtOwG0> Ml30SG1UVw>? NXvLN3dYcW6mdXPld{BCeG:ydH;zbZM> NHW2TmQzPjl{OEW3PC=>
A549 M1HNVGZ2dmO2aX;uJIF{e2G7 MViwMlXjiIsQvF2= MWfEUXNQ NWXMT5k4emWmdXPld{B4d3WwZDDjcI9{fXKn NILmdmwzPjl{OEW3PC=>
NCI-H358 M3\wcmZ2dmO2aX;uJIF{e2G7 NFLKNmkxNjYkgJtOwG0> MVjEUXNQ MlfJdoVlfWOnczD3c5Vv\CClbH;zeZJm NGC1OYwzPjl{OEW3PC=>

... Click to View More Cell Line Experimental Data

In vivo BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Kinase inhibition assays:

The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:[1]
+ Expand
  • Cell lines: IGF-1R-Sal, RH41 and Geo cell lines
  • Concentrations: 365 nM
  • Incubation Time: 72 hours
  • Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice
  • Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol)
  • Dosages: 150 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.49
Formula

C23H24FN9O

CAS No. 1001350-96-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01525823 Completed Healthy Volunteers Bristol-Myers Squibb February 2012 Phase 1
NCT01525823 Completed Healthy Volunteers Bristol-Myers Squibb February 2012 Phase 1
NCT01225172 Completed Breast Cancer Bristol-Myers Squibb|Mayo Clinic December 2010 Phase 2
NCT01225172 Completed Breast Cancer Bristol-Myers Squibb|Mayo Clinic December 2010 Phase 2
NCT00908024 Terminated Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis Bristol-Myers Squibb October 2009 Phase 1|Phase 2
NCT00908024 Terminated Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis Bristol-Myers Squibb October 2009 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Tags: buy BMS-754807 | BMS-754807 supplier | purchase BMS-754807 | BMS-754807 cost | BMS-754807 manufacturer | order BMS-754807 | BMS-754807 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID